Table 3. Association of Lp-PLA2 with total CVD.
VariablesHR (95% CI) by quartile of Lp-PLA2aP for trend
Q1Q2Q3Q4
Lp-PLA2 activity
    Adjusted for age and race/ethnicity1.001.23 (1.00–1.50)1.22 (1.00–1.49)1.55 (1.27–1.88)<0.0001
    MV1b1.001.27 (1.03–1.56)1.19 (0.97–1.47)1.55 (1.26–1.92)0.0002
    MV21.001.18 (0.95–1.48)0.96 (0.76–1.21)1.02 (0.79–1.33)0.65
    MV31.001.21 (0.97–1.51)1.00 (0.79–1.27)1.08 (0.83–1.40)0.95
    ATP variablesc1.001.16 (0.93–1.44)0.93 (0.74–1.17)0.99 (0.77–1.28)0.48
    RRS variablesd1.001.21 (0.97–1.50)1.00 (0.80–1.27)1.09 (0.85–1.40)0.96
Lp-PLA2 mass
    Adjusted for age and race/ethnicity1.001.12 (0.91–1.37)1.40 (1.15–1.72)1.74 (1.43–2.10)<0.0001
    MV11.001.14 (0.93–1.41)1.49 (1.21–1.84)1.77 (1.45–2.17)<0.0001
    MV21.001.26 (1.00–1.57)1.42 (1.14–1.79)1.75 (1.39–2.21)<0.0001
    MV31.001.25 (1.00–1.57)1.47 (1.17–1.86)1.84 (1.45–2.34)<0.0001
    ATP variables1.001.25 (1.00–1.56)1.40 (1.12–1.76)1.74 (1.38–2.18)<0.0001
    RRS variables1.001.24 (0.99–1.56)1.46 (1.16–1.84)1.86 (1.47–2.35)<0.0001
  • a Quartile cut points are 146.5, 179.3, and 212.1 mmol/min/mL for activity and 387.3, 475.1, and 572.4 ng/mL for mass.

  • b MV1, adjusted for age and race/ethnicity, plus current conditions and medication, including prior diabetes, angina, statin use, and current and past hormone therapy. MV2, additionally adjusted for traditional cardiovascular risk factors, including current smoking and the natural logs of SBP, total and high-density lipoprotein cholesterol. MV3, additionally adjusted for the natural log of CRP, family history of premature MI, and Hb A1c among diabetics.

  • c ATP variables, adjusted for age, current smoking, prior diabetes, and the natural logs of SBP and total and HDL cholesterol.

  • d RRS variables, adjusted for age, current smoking, family history of premature MI, prior diabetes, and Hb A1c among diabetics, and the natural logs of SBP, total and HDL cholesterol, and CRP.